化学信息:
化学名
|
5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide
|
|
简称
|
Vilazodone
|
别名
|
EMD 68843, SB 659746A, EMD-68843, EMD68843, SB-659746A, SB659746A
|
中文名
|
维拉佐酮
|
化学式
|
C26H27N5O2
|
分子量
|
441.52
|
CAS号
|
163521-12-8
|
纯度
|
98%
|
溶剂/溶解度
|
Water<1mg/ml; DMSO5mg/ml; Ethanol<1mg/ml
|
溶液配制
|
5mg加入1.13ml DMSO,或者每4.42mg加入1ml DMSO,配制成10mM溶液。SD2452-10mM用DMSO配制。
|
生物信息:
产品描述
|
Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.
|
信号通路
|
GPCR & G Protein; Neuronal Signaling
|
靶点
|
SSRI
|
5-HT1A
|
-
|
-
|
-
|
IC50
|
-
|
-
|
-
|
-
|
-
|
体外研究
|
Vilazodone represents another option for the treatment of MDD. Vilazodone appears to have a favourable weight-gain profile based on short-term studies. Sexual side-effects were not consistently demonstrated when assessed using clinical rating scales but spontaneously reported AEs related to sexual functioning were observed. Additional controlled data regarding long-term efficacy and effectiveness will help characterise this new agent when used in maintenance treatment.
|
体内研究
|
N/A
|
临床实验
|
N/A
|
特征
|
N/A
|
相关实验数据(此数据来自于公开文献,碧云天并不保证其有效性):
酶活性检测实验
|
方法
|
N/A
|
细胞实验
|
细胞系
|
N/A
|
浓度
|
N/A
|
处理时间
|
N/A
|
方法
|
N/A
|
动物实验
|
动物模型
|
N/A
|
配制
|
N/A
|
剂量
|
N/A
|
给药方式
|
N/A
|
参考文献:
1. Lee A. Dawson et al. Neuroscience & Therapeutics. 2009 June, 15(2), 107-117.
2. Thomas L. Psychopharmacology. 2011 June, 1(3), 81-87.
3. Cruz MP. P T. 2012 Jan, 37(1), 28-31.
4. Reed CR, Kajdasz DK, Whalen H, Athanasiou MC, Gallipoli S, Thase ME. Curr Med Res Opin. 2012 Jan, 28(1), 27-39.
包装清单:
产品编号
|
产品名称
|
包装
|
SD2452-10mM
|
Vilazodone (SSRI抑制剂)
|
10mM×0.2ml
|
SD2452-5mg
|
Vilazodone (SSRI抑制剂)
|
5mg
|
SD2452-25mg
|
Vilazodone (SSRI抑制剂)
|
25mg
|
—
|
说明书
|
1份
|
保存条件:
-20℃保存,至少一年有效。5mg和25mg包装也可室温保存,至少6个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。
注意事项:
本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。
为了您的安全和健康,请穿实验服并戴一次性手套操作。